0000000000102110

AUTHOR

Sibylle Schliemann

showing 2 related works from this author

Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany

2021

Background. Comprehensive data on the epidemiology and comorbidities of chronic urticaria (CU) in Germany are either limited, or not contemporary. Objectives. To investigate the epidemiology of CU, overall comorbidities and healthcare resource utilized by patients with CU in Germany, using an anonymized statutory health insurance (SHI) database. Methods. Anonymized SHI claims research database of the Institute for Applied Health Research, Berlin [InGef] (01 January 2015-30 September 2018) was used to analyse insured individuals with a confirmed diagnosis of CU (ICD-10-GM codes). Twelve-month diagnosed prevalence and incidence, comorbidities (vs. atopic dermatitis and psoriasis), and healthc…

AdultMalemedicine.medical_specialtyUrticariaPopulation610Dermatologychronic urticariaGermanyPsoriasisInternal medicineHealth careEpidemiologyHumansMedicineddc:610ChildeducationChronic urticariaeducation.field_of_studybusiness.industryIncidence (epidemiology)healthcare utilizationAtopic dermatitisPatient Acceptance of Health Caremedicine.diseasecomorbidityInfectious DiseasesHealthcare utilizationChronic DiseaseFemaleepidemiologybusiness600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
researchProduct

The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

2021

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers o…

Male0301 basic medicineSTRESSExacerbationUCAREpandemijeMedizinOmalizumabOmalizumabSERUMchronic urticaria0302 clinical medicinePandemicHealth careImmunology and AllergyChronic UrticariatreatmentChronic urticaria; COVID-19; Cyclosporine; Omalizumab; Pandemic; SARS-CoV-2; Treatment; UCAREzdravljenjeASSOCIATIONMiddle AgedCOVID-19; SARS-CoV-2; UCARE; chronic urticaria; cyclosporine; omalizumab; pandemic; treatmentkronična urtikarijaINFECTIONSGA(2)LENCyclosporineFemale600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheitmedicine.drugAdultmedicine.medical_specialtyAdolescentCoronavirus disease 2019 (COVID-19)Immunology610udc:616-097pandemicsciklosporinYoung Adult03 medical and health sciencesPatient referralmedicineHumansIn patientPatient Reported Outcome MeasurescyclosporineChronic urticariaAgedInternetPandemicSARS-CoV-2business.industrypandemicCOVID-19TreatmentDEFINITIONMedicine; Allergy; ImmunologyCross-Sectional Studies030104 developmental biology030228 respiratory systemEmergency medicineomalizumabbusinessAllergy: European Journal of Allergy and Clinical Immunology
researchProduct